Physician profile
Mark Armando Prendes
NPI 1073874954
$9,132.48
in general payments reported to CMS, 2019-2025
17 companies · $61.29 in 2025
The $61.29 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $82.86 · 2021: $30.35 · 2022: $8,255 · 2023: $223 · 2024: $351 · 2025: $61.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $7,917.21 | 2022 | |
| Amgen INC. | $344.14 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $230.60 | 2021-2023 | Tepezza |
| Genentech USA, INC. | $137.66 | 2022 | |
| Alimera Sciences, INC. | $88.89 | 2019-2021 | |
| Shire North American Group INC | $72.36 | 2019 | |
| Biotissue Holdings INC. | $61.93 | 2023 | |
| Novartis Pharmaceuticals Corporation | $61.10 | 2022 | |
| Genentech, INC. | $46.80 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $25.43 | 2025 | Xdemvy |
| Alcon Vision LLC | $24.90 | 2024 | |
| Aerie Pharmaceuticals, INC. | $24.51 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $20.04 | 2020 | |
| Apellis Pharmaceuticals, INC. | $19.80 | 2023 | Syfovre |
| Bausch & Lomb Americas INC. | $19.49 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $19.45 | 2020 | |
| Rayner Intraocular Lenses Limited | $18.17 | 2024 | Omidria |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Prendes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.